Item 310 | First Year - FY2003 | Second Year - FY2004 |
|---|---|---|
| Communicable and Chronic Disease Prevention and Control (40500) | $48,219,157 | $48,219,157 |
| Cancer Prevention and Control (40501) | FY2003 $676,343 | FY2004 $676,343 |
| Immunization Services (40502) | FY2003 $6,739,526 | FY2004 $6,739,526 |
| Tuberculosis Prevention and Control (40503) | FY2003 $1,370,340 | FY2004 $1,370,340 |
| Venereal Disease Prevention and Control (40504) | FY2003 $1,655,682 | FY2004 $1,655,682 |
| Epidemiological Services (40505) | FY2003 $2,736,788 | FY2004 $2,736,788 |
| Acquired Immune Deficiency Prevention and Treatment Services (40506) | FY2003 $22,702,402 | FY2004 $22,702,402 |
| Technical Assistance and Support for Prevention and Control of Communicable and Chronic Diseases (40507) | FY2003 $5,382,462 | FY2004 $5,382,462 |
| Financial Assistance for Health Prevention and Promotion (40508) | FY2003 $6,955,614 | FY2004 $6,955,614 |
| Fund Sources: | ||
| General | FY2003 $11,867,333 | FY2004 $11,867,333 |
| Special | FY2003 $608,756 | FY2004 $608,756 |
| Federal Trust | FY2003 $35,743,068 | FY2004 $35,743,068 |
Authority: §§ 32.1-11.1 through 32.1-11.2, 32.1-35 through 32.1-73.4, Code of Virginia; and P.L. 91-464, as amended, Federal Code.
A. Out of this appropriation, $1,325,000 the first year and $1,325,000 the second year is provided from the general fund to support the regional AIDS resource and consultation centers and one local early intervention and treatment center.
B. Out of this appropriation, $150,000 the first year and $150,000 the second year is provided from the general fund to support the Arthur Ashe Health Center in Richmond.
C. Appropriations from this Item included for sexual assault centers may be used for adult and children's services provided by the centers and for the sexual assault hotline.
D. Out of this appropriation, $50,000 the first year and $50,000 the second year from the general fund shall be provided to the Fan Free Clinic for AIDS related services.
E. The General Assembly finds that access to pharmaceutical therapies is important for treating HIV patients and that patients should have access to a wide range of treatment options as determined under consultation with a physician. The Department shall examine clinical evidence and national guidelines quarterly in order to determine whether additional appropriate forms of treatment and funding for these treatments should be made available through the Virginia HIV Medications Assistance Program. The Department shall report by December 1 of each year to the Joint Subcommittee Studying HIV on its findings and recommendations resulting from an examination of new therapies, including what, if any, additional treatment options and funding should be made available through the Virginia HIV Medications Assistance Program.